CoChat

Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis

Open access
Huang, Peng, Kaluba, Benson, Jiang, Xiao-lin, Chang, Shi, Tang, Xiao-feng, Mao, Lin-feng, Zhang, Zhi-peng, Huang, Fei-zhou · 2018 · BioMed Research International

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Abnormal metabolism of cholesterol may be a contributing factor in nonalcoholic steatohepatitis (NASH) pathogenesis. Accumulating evidence has shown that liver X receptor (LXR) is closely related to intrahepatic inflammation and fibrosis. In this study, we evaluated the effects of a novel liver-specific LXR inverse agonist, SR9243, on antifibrosis in NASH mice. A high-cholesterol diet was employed to induce NASH in BALB/c mice by either carbon tetrachloride (CCL4) administration or bile-duct ligation (BDL). Once NASH was induced, mice were treated with SR9243 for one month by intraperitoneal (i.p.) injection. Liver tissues were collected to determine the degree of fibrosis and intrahepatic inflammation via pathological examination and QPCR; serum was collected to analyze the plasma lipid levels and liver function by clinical biochemistry. The mice developed hepatic steatosis, severe hepatic inflammation, and fibrosis by BDL or CCL4. Treatment with SR9243 significantly reduced the severity of hepatic inflammation and ameliorated hepatic fibrosis; simultaneously, body weight, serum glucose, and plasma lipid levels were controlled effectively. Our data demonstrate that SR9243 exerts an antifibrotic and anti-inflammatory effect in NASH mice; hence these findings highly suggest that LXR inverse agonist could be therapeutically important in NASH treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2018/8071093

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of SR9243 on liver fibrosis induced by BDL or CCL4 treatment. After being fed a control or HC diet for 4 weeks, BALB/c mice were subjected to (a, b) 3-week BDL or (c, d) CCl4 treatment twice a week for 4 weeks to induce NASH model (n = 6/group). ((a) and (c)) H&E-stained sections and Masson trichrome-stained sections in representative liver samples. ((b) and (d)) Quantification of Masson trichrome staining, liver hydroxyproline concentrations, and hepatic expression of collagen 1α1 and collagen 1α2. ∗∗P < 0.01.
Figure 1 Effects of SR9243 on liver fibrosis induced by BDL or CCL4 treatment. After being fed a control or HC diet for 4 weeks, BALB/c mice were subjected to (a, b) 3-week BDL or (c, d) CCl4 treatment twice a week for 4 weeks to induce NASH model (n = 6/group). ((a) and (c)) H&E-stained sections and Masson trichrome-stained sections in representative liver samples. ((b) and (d)) Quantification of Masson trichrome staining, liver hydroxyproline concentrations, and hepatic expression of collagen 1α1 and collagen 1α2. ∗∗P < 0.01.CC BY · PubMed Central
Figure 2 Effects of SR9243 on hepatocyte injury induced by BDL or CCL4 treatment. (a) Fasting insulin levels are shown in the middle panel; glucose levels are illustrated in the right panel. (b) Total cholesterol, LDL, and plasma triglycerides were determined from mouse plasma samples at the termination of the experiment. (c) Liver enzyme levels changed during the treatment. ∗P < 0.05 and ∗∗P < 0.01.
Figure 2 Effects of SR9243 on hepatocyte injury induced by BDL or CCL4 treatment. (a) Fasting insulin levels are shown in the middle panel; glucose levels are illustrated in the right panel. (b) Total cholesterol, LDL, and plasma triglycerides were determined from mouse plasma samples at the termination of the experiment. (c) Liver enzyme levels changed during the treatment. ∗P < 0.05 and ∗∗P < 0.01.CC BY · PubMed Central
Figure 3 Effects of SR9243 on hepatic proinflammatory cytokines expression induced by BDL or CCL4 treatment. mRNA levels of CD68, TNF-α, IL-1β, and IL-6 were tested in liver tissues by QPCR, ∗∗P < 0.01.
Figure 3 Effects of SR9243 on hepatic proinflammatory cytokines expression induced by BDL or CCL4 treatment. mRNA levels of CD68, TNF-α, IL-1β, and IL-6 were tested in liver tissues by QPCR, ∗∗P < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 47

Metadata

Authors
Huang, P., Kaluba, B., Jiang, X.-L., Chang, S., Tang, X.-F., Mao, L.-F., Zhang, Z.-P., & Huang, F.-Z.
Affiliations
  • Central South University (CN)
  • Yangtze University (CN)
  • Department of General Surgery, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, China
  • Department of General Surgery, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Changsha 410013, China
Venue
BioMed Research International
Publisher
Wiley
Published
2018
Volume
2018
Pages
1-7
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
OpenAlex
W2789257932
Cited by
44
References
26
Citations by year
2026: 5 · 2025: 4 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 7
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Hunan Provincial Innovation Foundation for Postgraduate (CX2017B073)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
liver X receptor, nonalcoholic steatohepatitis, liver fibrosis, intrahepatic inflammation, cholesterol metabolism, bile duct ligation, carbon tetrachloride, high-cholesterol diet, hepatic steatosis, plasma lipid levels, antifibrotic therapy
MeSH terms
Liver X Receptors, Animals, Bile Ducts, Blood Glucose, Body Weight, Carbon Tetrachloride, Inflammation, Insulin, Ligation, Lipids, Liver, Liver Cirrhosis, Male, Mice, Inbred BALB C, RNA, Messenger, Sulfonamides, Cytokines, Inflammation Mediators, Hepatocytes, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis. https://app.cochat.ai/papers/10.1155/2018/8071093
The paper
Huang, P., Kaluba, B., Jiang, X.-L., Chang, S., Tang, X.-F., Mao, L.-F., Zhang, Z.-P., & Huang, F.-Z. (2018). Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis. BioMed Research International. https://doi.org/10.1155/2018/8071093

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.